Top entities: ImmunityBio, Patrick Soon-Shiong.

What category does this event fall under?

Business — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 15, 2026. Coverage continues to evolve.

Business class action

ImmunityBio Class Action Lawsuit Filed

Q: When did this event occur?

First reported May 01, 2026; last updated May 15, 2026.

Q: What is the market impact?

Direct. The class action lawsuit against ImmunityBio could lead to a significant financial penalty and reputational damage for the company, potentially causing its stock price to decline.

Analysis based on 6 articles · First reported May 01, 2026 · Last updated May 15, 2026

Sentiment

-40

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The class action lawsuit against ImmunityBio could lead to a significant financial penalty and reputational damage for the company, potentially causing its stock price to decline. Investors who purchased shares during the class period may recover losses, while the legal firm stands to gain from the litigation.

Biotechnology Legal Services

Event Summary

The Gross Law Firm has issued a notice to shareholders of ImmunityBio (NASDAQ: IBRX) regarding a class action lawsuit. The lawsuit alleges that during the period of January 19, 2026, to March 24, 2026, ImmunityBio and defendant Patrick Soon-Shiong made materially false and misleading statements, specifically overstating Anktiva's capabilities. These alleged misrepresentations led to an artificial inflation of ImmunityBio's stock price. Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline of May 26, 2026, to seek lead plaintiff appointment. The Gross Law Firm aims to protect investors who suffered losses due to deceit and illegal business practices.

Key Actions

100 ImmunityBio overstated capabilities

Entities Involved

stock

ImmunityBio

ImmunityBio is the defendant in a class action lawsuit alleging that its statements about Anktiva's capabilities were materially false and misleading, which could negatively impact its stock price and reputation.

Importance 100 Sentiment -50

per

Patrick Soon-Shiong

Patrick Soon-Shiong is a defendant in the class action lawsuit, accused of materially overstating Anktiva's capabilities.

Importance 80 Sentiment -40

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard